File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Potential beneficial effect of ergothioneine in protecting endothelial dysfunction

TitlePotential beneficial effect of ergothioneine in protecting endothelial dysfunction
Authors
KeywordsPharmacy and pharmacology environmental studies
Toxicology and environmental safety
Issue Date2010
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO
Citation
The 16th World Congress on Basic and Clinical Pharmacology (WorldPharma2010), Copenhagen, Denmark, 17-23 July 2010. In Basic & Clinical Pharmacology & Toxicology, 2010, v. 107, suppl. 1, p. 583 How to Cite?
AbstractEndothelial function is often impaired in diabetic patients, leading to various pathophysiological processes in cardiovascular diseases. A number of evidence has also demonstrated that reactive oxygen species is one of the major factors for diabetic endothelial dysfunction. Ergothioneine, a chemical rich in mushroom, has been proposed to possess potent antioxidant activities, involving the removal of cell toxic radical species or chelating of metal ions. However, the biological relevance of these findings is unclear because most of the preceding studies were performed in cell-free systems. In this study, we aimed to investigate if ergothioneine can enter endothelial cells and protect endothelial cells against diabetes-induced damage. Human brain microvascular endothelial cells (HBMECs) were used in this study. Ergothioneine is a transport substrate of organic cation transporter novel type 1 (OCTN-1) and our result of RT-PCR and Western blotting showed that OCTN-1 was present in HBMECs. HBMECs were incubated in 5 mM (control) and 25 mM glucose medium (which mimicked the hyperglycemia in diabetes) in the absence of presence of ergothioneine. By means of MTT assay, we found that the viability of HBMECs was significantly lowered in 25 mM glucose condition but this detrimental effect of high glucose could be reduced by ergothioneine, at a concentration as low as 10 nM. In conclusion, our result suggests that ergothioneine can be taken up by endothelial cells and may be a potential protective agent that can protect endothelial cells, particularly in the case of diabetes
DescriptionFocused Conference Group: P15 – Endothelium in Health And Disease Potential Beneficial Effect of Ergothioneine in Protecting Endothelial Dysfunction. Paper No. 1649
Persistent Identifierhttp://hdl.handle.net/10722/126883
ISSN
2015 Impact Factor: 3.097
2015 SCImago Journal Rankings: 0.539

 

DC FieldValueLanguage
dc.contributor.authorSit, ASMen_HK
dc.contributor.authorHo, EYWen_HK
dc.contributor.authorLi, RWSen_HK
dc.contributor.authorKwan, YWen_HK
dc.contributor.authorHausman, Men_HK
dc.contributor.authorVanhoutte, PMen_HK
dc.contributor.authorLeung, GPHen_HK
dc.date.accessioned2010-10-31T12:54:08Z-
dc.date.available2010-10-31T12:54:08Z-
dc.date.issued2010en_HK
dc.identifier.citationThe 16th World Congress on Basic and Clinical Pharmacology (WorldPharma2010), Copenhagen, Denmark, 17-23 July 2010. In Basic & Clinical Pharmacology & Toxicology, 2010, v. 107, suppl. 1, p. 583en_HK
dc.identifier.issn1742-7835-
dc.identifier.urihttp://hdl.handle.net/10722/126883-
dc.descriptionFocused Conference Group: P15 – Endothelium in Health And Disease Potential Beneficial Effect of Ergothioneine in Protecting Endothelial Dysfunction. Paper No. 1649-
dc.description.abstractEndothelial function is often impaired in diabetic patients, leading to various pathophysiological processes in cardiovascular diseases. A number of evidence has also demonstrated that reactive oxygen species is one of the major factors for diabetic endothelial dysfunction. Ergothioneine, a chemical rich in mushroom, has been proposed to possess potent antioxidant activities, involving the removal of cell toxic radical species or chelating of metal ions. However, the biological relevance of these findings is unclear because most of the preceding studies were performed in cell-free systems. In this study, we aimed to investigate if ergothioneine can enter endothelial cells and protect endothelial cells against diabetes-induced damage. Human brain microvascular endothelial cells (HBMECs) were used in this study. Ergothioneine is a transport substrate of organic cation transporter novel type 1 (OCTN-1) and our result of RT-PCR and Western blotting showed that OCTN-1 was present in HBMECs. HBMECs were incubated in 5 mM (control) and 25 mM glucose medium (which mimicked the hyperglycemia in diabetes) in the absence of presence of ergothioneine. By means of MTT assay, we found that the viability of HBMECs was significantly lowered in 25 mM glucose condition but this detrimental effect of high glucose could be reduced by ergothioneine, at a concentration as low as 10 nM. In conclusion, our result suggests that ergothioneine can be taken up by endothelial cells and may be a potential protective agent that can protect endothelial cells, particularly in the case of diabetes-
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO-
dc.relation.ispartofBasic & Clinical Pharmacology & Toxicologyen_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectPharmacy and pharmacology environmental studies-
dc.subjectToxicology and environmental safety-
dc.titlePotential beneficial effect of ergothioneine in protecting endothelial dysfunctionen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1742-7835&volume=107, suppl. 1&spage=583&epage=&date=2010&atitle=Potential+beneficial+effect+of+ergothioneine+in+protecting+endothelial+dysfunction-
dc.identifier.emailHo, EYW: eywho@graduate.hku.hken_HK
dc.identifier.emailLi, RWS: h0594069@hkusua.hku.hken_HK
dc.identifier.emailVanhoutte, PM: vanhoutt@hku.hken_HK
dc.identifier.emailLeung, GPH: leung_pak_heng@hotmail.comen_HK
dc.identifier.hkuros175280en_HK
dc.identifier.volume107, suppl. 1en_HK
dc.identifier.spage583en_HK
dc.identifier.epage583-
dc.description.otherThe 16th World Congress on Basic and Clinical Pharmacology (WorldPharma2010), Copenhagen, Denmark, 17-23 July 2010. In Basic & Clinical Pharmacology & Toxicology, 2010, v. 107, suppl. 1, p. 583-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats